# STAA — Staar Surgical Co · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** STAA  
**Sources:** 22  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-staa-staar-surgical-co-catalysts-narrative-risks-9808

---

## STAAR Surgical (STAA) — Snapshot as of 2026-10-28

As of October 28, 2026, STAA trades at roughly **$24.40–$24.50**, with a market capitalization of approximately **$1.21–$1.24 billion** [[12]](https://finance.yahoo.com/markets/stocks/articles/staar-surgical-staa-fallen-far-111522377.html)[[16]](https://www.marketbeat.com/stocks/NASDAQ/STAA/)[[17]](https://finance.yahoo.com/quote/STAA/)[[19]](https://stockanalysis.com/stocks/staa/). It remains inside a 52-week range of $15.59 to $35.87, i.e., well below its highs [[17]](https://finance.yahoo.com/quote/STAA/)[[19]](https://stockanalysis.com/stocks/staa/). This is slightly higher than the ~$1.16B market cap noted on our calendar as of 2026-10-27, consistent with the recent price recovery rather than any data error. The company designs, develops, manufactures, and sells phakic implantable lenses (its flagship is the EVO Visian Implantable Collamer Lens family) and markets them in 75+ countries, having sold over 4 million lenses [[16]](https://www.marketbeat.com/stocks/NASDAQ/STAA/)[[19]](https://stockanalysis.com/stocks/staa/)[[20]](https://www.staar.com/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-staa-staar-surgical-co-catalysts-narrative-risks-9808 (free to sign up)._